Back to search

Article

Levels of Pretreatment Blood Lipids are Prognostic Factors in Advanced NSCLC Patients Treated with Anlotinib

2021-09-07

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC).<sup> </sup>Results from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients.<sup> </sup>Although numerous inflammatory biomarkers play a vital role...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8abe672f-be70-5ae3-ade4-ca8709f66b96
DOI
10.21203/rs.3.rs-864724/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Levels of Pretreatment Blood Lipids are Prognostic Factors in Advanced NSCLC Patients Treated with AnlotinibDOI 10.21203/rs.3.rs-864724/v1
Pretreatment HDL-C and ApoA1 are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with TKI.Semantic proximity
Lipidomics reveals biomarkers of the efficacy of first-line ICIs therapy combined with chemotherapy in NSCLCSemantic proximity
Effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancerSemantic proximity
Screening anlotinib responders via blood-based proteomics in non-small cell lung cancerSemantic proximity
High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments.Semantic proximity
High Body Mass Index Was Related to Favorable Therapeutic Efficacy of Epidermal Growth Factor Receptor Targeted Therapy in Advanced Non-Small Cell Lung CancerSemantic proximity
Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations.Semantic proximity
The Percentage of ALK-Positive Cells and the Efficacy of First-Line Alectinib in Advanced Non-small Cell Lung Cancer: Is it a novel factor for stratification? (Turkish Oncology Group Study)Semantic proximity
A Latent Class Analysis Based on Nutritional and Inflammatory Profiles Predicts Efficacy in Advanced NSCLC Treated with Immune Checkpoint InhibitorsSemantic proximity
Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.Semantic proximity
Prognostic Value of Baseline HbA1c in Advanced Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Retrospective Cohort StudySemantic proximity
Association of mean platelet volume (MPV), MPV/PLATELET (PLT) ratio, and lymphocyte/monocyte ratio (LMR) as poor prognostic factor in EGFR-mutant lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor.Semantic proximity
Select a neighboring publication to make it the new centre.